Abstract 249P
Background
Abnormal uterine bleeding is the most common complaint in women attending to physicians, especially in the peri-menopausal and post-menopausal period which is reported to account for 70% of all gynecological consultations. The main aim of investigations for abnormal uterine bleeding is to rule out intrauterine pathology, particularly endometrial cancer or atypical hyperplasia.The study was aimed to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of endometrial biopsy with Pipelle in women with abnormal uterine bleeding compared to D&C (reference standard) and sufficiency of the obtained endometrial tissue of two techniques.
Methods
Literature for studies published between 1965 and 2019 comparing the results of Pipelle with findings by D&C was searched. The QUADAS 2 tool was performed to evaluate the risk and applicability of each study. The diagnostic accuracy of Pipelle was evaluated through calculation of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio with pooled proportion.
Results
A total of 8 studies and 1675 patients were included in this meta-analysis. The pooled sensitivity of endometrial sampling by Pipelle was 70.9% (95%CI: 58.1%-81.1%) in endometrial tumor, 97.2% (95%CI: 95.5%-98.3%) in endometrial benign disease, and 94.4% (95%CI 92.7%-95.8%) in normal endometrium. The pooled specificity of Pipelle was 99.6% (95%CI: 99.0%-99.9%) in endometrial tumor, 74.7% (95% 56.4%-87.1%) in endometrial benign disease, and 90.0% (95%CI 75.5%-96.3%) in normal endometrium. The positive likelihood ratio by Pipelle in the diagnosis of endometrial tumor, benign disease and normal endometrium was 191.06 (95%CI 70.81-515.48), 28.86 (95%CI 15.10-55.19) and 9.573 (95%CI 4.28-21.40), while the negative likelihood ratio by Pipelle was 0.337 (95%CI 0.236-0.482), 0.241 (95%CI 0.131-0.444) and 0.07 (95%CI 0.04-0.11), respectively. The highest DOR 851.68 was achieved in the result of endometrial tumor.
Conclusions
Pipelle can be introduced as a suitable alternative of diagnostic curettage. When an adequate specimen is obtained, a positive test result is more accurate for ruling in disease than a negative test result for ruling it out.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract